Pfiz­er re-ups on Mis­sion Ther­a­peu­tics col­lab­o­ra­tion, lead­ing a $15M round and grab­bing first dibs on DUBs

Sev­en years af­ter Pfiz­er first in­vest­ed in Mis­sion Ther­a­peu­tics, a biotech that re­search­es se­lec­tive­ly in­hibit­ing deu­biq­ui­ty­lat­ing en­zymes (DUBs), the phar­ma gi­ant is re-up­ping its com­mit­ment to the com­pa­ny in an­oth­er sign of con­fi­dence in the field of pro­tein degra­da­tion.

Pfiz­er’s VC arm is head­ing up a $15 mil­lion round, an­nounced Mon­day morn­ing, and in­creas­ing its over­all stake in Mis­sion. Pfiz­er is al­so en­ter­ing in­to a li­cens­ing agree­ment that would give it first dibs at ne­go­ti­at­ing ex­clu­siv­i­ty af­ter ac­cess­ing cer­tain DUB in­hibitors and screen­ing them for their po­ten­tial as drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER